Hyperhomocysteinemia in patients with epilepsy: Does it play a role in the pathogenesis of brain atrophy? A preliminary report

Gaetano Gorgone, Daniela Caccamo, Laura Rosa Pisani, Monica Currò, Giulia Parisi, Giancarla Oteri, Riccardo Ientile, Paolo Maria Rossini, Francesco Pisani

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: Brain atrophy (BA) is observed in 20-50% of patients with epilepsy. Hyper-total-homocysteinemia (hyper-tHcy), which occurs in 10-40% of patients, is considered to be a risk factor for cardiovascular diseases and BA. The present study was aimed at investigating the possible association of hyper-tHcy with BA in a population of patients with epilepsy. Methods: Fifty-eight patients (33 M/25 F, 43.5 ± 13.1 years of age) chronically treated with antiepileptic drugs (AEDs) and 60 controls matched for age and sex were enrolled. All participants underwent determination of plasma tHcy, folate, vitamin B12, and C677T methylene-tetrahydrofolate-reductase (MTHFR) polymorphism genotyping, and brain magnetic resonance imaging (MRI). Results: Patients exhibited significantly higher tHcy and lower folate levels than controls; hyper-tHcy was significantly associated with the variables group (patients vs. controls), MTHFR genotype, and their interaction terms. BA was observed in 30.1% of patients and was significantly associated with hyper-tHcy (β = 0.45, p = 0.003) and polytherapy (β = 0.31, p <0.001). Discussion: Our investigation suggests that hyper-tHcy plays a role in the development of BA in patients with epilepsy. Although the real origin of this phenomenon is not yet fully elucidated, experimental data support the hypothesis of a link of the neuronal Hcy-mediated damage with oxidative stress and excitotoxicity.

Original languageEnglish
Pages (from-to)33-36
Number of pages4
JournalEpilepsia
Volume50
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Hyperhomocysteinemia
Atrophy
Epilepsy
Brain
Methylenetetrahydrofolate Reductase (NADPH2)
Folic Acid
Drug and Narcotic Control
Vitamin B 12
Anticonvulsants
Oxidative Stress
Cardiovascular Diseases
Genotype
Magnetic Resonance Imaging
Homocysteinemia

Keywords

  • Brain atrophy
  • C677T MTHFR polymorphism
  • Enzyme-inducing antiepileptic drugs
  • Hyper-total-homocysteinemia

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Gorgone, G., Caccamo, D., Pisani, L. R., Currò, M., Parisi, G., Oteri, G., ... Pisani, F. (2009). Hyperhomocysteinemia in patients with epilepsy: Does it play a role in the pathogenesis of brain atrophy? A preliminary report. Epilepsia, 50(SUPPL. 1), 33-36. https://doi.org/10.1111/j.1528-1167.2008.01967.x

Hyperhomocysteinemia in patients with epilepsy : Does it play a role in the pathogenesis of brain atrophy? A preliminary report. / Gorgone, Gaetano; Caccamo, Daniela; Pisani, Laura Rosa; Currò, Monica; Parisi, Giulia; Oteri, Giancarla; Ientile, Riccardo; Rossini, Paolo Maria; Pisani, Francesco.

In: Epilepsia, Vol. 50, No. SUPPL. 1, 01.2009, p. 33-36.

Research output: Contribution to journalArticle

Gorgone, G, Caccamo, D, Pisani, LR, Currò, M, Parisi, G, Oteri, G, Ientile, R, Rossini, PM & Pisani, F 2009, 'Hyperhomocysteinemia in patients with epilepsy: Does it play a role in the pathogenesis of brain atrophy? A preliminary report', Epilepsia, vol. 50, no. SUPPL. 1, pp. 33-36. https://doi.org/10.1111/j.1528-1167.2008.01967.x
Gorgone, Gaetano ; Caccamo, Daniela ; Pisani, Laura Rosa ; Currò, Monica ; Parisi, Giulia ; Oteri, Giancarla ; Ientile, Riccardo ; Rossini, Paolo Maria ; Pisani, Francesco. / Hyperhomocysteinemia in patients with epilepsy : Does it play a role in the pathogenesis of brain atrophy? A preliminary report. In: Epilepsia. 2009 ; Vol. 50, No. SUPPL. 1. pp. 33-36.
@article{3099fdfe6359465b8649fdcec2f3ab62,
title = "Hyperhomocysteinemia in patients with epilepsy: Does it play a role in the pathogenesis of brain atrophy? A preliminary report",
abstract = "Purpose: Brain atrophy (BA) is observed in 20-50{\%} of patients with epilepsy. Hyper-total-homocysteinemia (hyper-tHcy), which occurs in 10-40{\%} of patients, is considered to be a risk factor for cardiovascular diseases and BA. The present study was aimed at investigating the possible association of hyper-tHcy with BA in a population of patients with epilepsy. Methods: Fifty-eight patients (33 M/25 F, 43.5 ± 13.1 years of age) chronically treated with antiepileptic drugs (AEDs) and 60 controls matched for age and sex were enrolled. All participants underwent determination of plasma tHcy, folate, vitamin B12, and C677T methylene-tetrahydrofolate-reductase (MTHFR) polymorphism genotyping, and brain magnetic resonance imaging (MRI). Results: Patients exhibited significantly higher tHcy and lower folate levels than controls; hyper-tHcy was significantly associated with the variables group (patients vs. controls), MTHFR genotype, and their interaction terms. BA was observed in 30.1{\%} of patients and was significantly associated with hyper-tHcy (β = 0.45, p = 0.003) and polytherapy (β = 0.31, p <0.001). Discussion: Our investigation suggests that hyper-tHcy plays a role in the development of BA in patients with epilepsy. Although the real origin of this phenomenon is not yet fully elucidated, experimental data support the hypothesis of a link of the neuronal Hcy-mediated damage with oxidative stress and excitotoxicity.",
keywords = "Brain atrophy, C677T MTHFR polymorphism, Enzyme-inducing antiepileptic drugs, Hyper-total-homocysteinemia",
author = "Gaetano Gorgone and Daniela Caccamo and Pisani, {Laura Rosa} and Monica Curr{\`o} and Giulia Parisi and Giancarla Oteri and Riccardo Ientile and Rossini, {Paolo Maria} and Francesco Pisani",
year = "2009",
month = "1",
doi = "10.1111/j.1528-1167.2008.01967.x",
language = "English",
volume = "50",
pages = "33--36",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Blackwell Publishing Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Hyperhomocysteinemia in patients with epilepsy

T2 - Does it play a role in the pathogenesis of brain atrophy? A preliminary report

AU - Gorgone, Gaetano

AU - Caccamo, Daniela

AU - Pisani, Laura Rosa

AU - Currò, Monica

AU - Parisi, Giulia

AU - Oteri, Giancarla

AU - Ientile, Riccardo

AU - Rossini, Paolo Maria

AU - Pisani, Francesco

PY - 2009/1

Y1 - 2009/1

N2 - Purpose: Brain atrophy (BA) is observed in 20-50% of patients with epilepsy. Hyper-total-homocysteinemia (hyper-tHcy), which occurs in 10-40% of patients, is considered to be a risk factor for cardiovascular diseases and BA. The present study was aimed at investigating the possible association of hyper-tHcy with BA in a population of patients with epilepsy. Methods: Fifty-eight patients (33 M/25 F, 43.5 ± 13.1 years of age) chronically treated with antiepileptic drugs (AEDs) and 60 controls matched for age and sex were enrolled. All participants underwent determination of plasma tHcy, folate, vitamin B12, and C677T methylene-tetrahydrofolate-reductase (MTHFR) polymorphism genotyping, and brain magnetic resonance imaging (MRI). Results: Patients exhibited significantly higher tHcy and lower folate levels than controls; hyper-tHcy was significantly associated with the variables group (patients vs. controls), MTHFR genotype, and their interaction terms. BA was observed in 30.1% of patients and was significantly associated with hyper-tHcy (β = 0.45, p = 0.003) and polytherapy (β = 0.31, p <0.001). Discussion: Our investigation suggests that hyper-tHcy plays a role in the development of BA in patients with epilepsy. Although the real origin of this phenomenon is not yet fully elucidated, experimental data support the hypothesis of a link of the neuronal Hcy-mediated damage with oxidative stress and excitotoxicity.

AB - Purpose: Brain atrophy (BA) is observed in 20-50% of patients with epilepsy. Hyper-total-homocysteinemia (hyper-tHcy), which occurs in 10-40% of patients, is considered to be a risk factor for cardiovascular diseases and BA. The present study was aimed at investigating the possible association of hyper-tHcy with BA in a population of patients with epilepsy. Methods: Fifty-eight patients (33 M/25 F, 43.5 ± 13.1 years of age) chronically treated with antiepileptic drugs (AEDs) and 60 controls matched for age and sex were enrolled. All participants underwent determination of plasma tHcy, folate, vitamin B12, and C677T methylene-tetrahydrofolate-reductase (MTHFR) polymorphism genotyping, and brain magnetic resonance imaging (MRI). Results: Patients exhibited significantly higher tHcy and lower folate levels than controls; hyper-tHcy was significantly associated with the variables group (patients vs. controls), MTHFR genotype, and their interaction terms. BA was observed in 30.1% of patients and was significantly associated with hyper-tHcy (β = 0.45, p = 0.003) and polytherapy (β = 0.31, p <0.001). Discussion: Our investigation suggests that hyper-tHcy plays a role in the development of BA in patients with epilepsy. Although the real origin of this phenomenon is not yet fully elucidated, experimental data support the hypothesis of a link of the neuronal Hcy-mediated damage with oxidative stress and excitotoxicity.

KW - Brain atrophy

KW - C677T MTHFR polymorphism

KW - Enzyme-inducing antiepileptic drugs

KW - Hyper-total-homocysteinemia

UR - http://www.scopus.com/inward/record.url?scp=58149286300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149286300&partnerID=8YFLogxK

U2 - 10.1111/j.1528-1167.2008.01967.x

DO - 10.1111/j.1528-1167.2008.01967.x

M3 - Article

C2 - 19125845

AN - SCOPUS:58149286300

VL - 50

SP - 33

EP - 36

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - SUPPL. 1

ER -